Skip to main content

Advertisement

Table 3 FEV 1 change from baseline at week 12 (day 84) by country, ITT population

From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

  VI 25 mcg OD (n = 101) SAL 50 mcg BD (n = 100) Placebo (n = 95)
Germany (N = 28) 62 (127.6) 175 (156.2) 19 (221.6)
Peru (N = 104) 391 (433.8) 360 (364.7) 492 (591.9)
Poland (N = 59) 279 (310.4) 251 (513.9) 117 (615.6)
Ukraine (N = 43) 158 (238.7) 127 (198.5) 200 (253.9)
United States (N = 62) 519 (568.2) 392 (756.0) 400 (522.5)
  1. Values are weighted mean (SD) 0–24 hour weighted mean serial FEV1 (ml).
  2. BD: twice-daily; FEV1: forced expiratory volume in one second; ITT: intent-to-treat; n: number of patients used in analysis; OD: once-daily; SAL: salmeterol; SD: standard deviation; VI: vilanterol.